Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

9.190 +0.040 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus Inc

< Previous 1 2 3 4 Next >
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Evolus
Via Business Wire
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®
From Evolus
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Recap: Evolus Q2 Earnings
  Evolus (NASDAQ:EOLS) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Needham Is Bullish On This Botox Equivalent Aesthetics Company
Via Benzinga
Recap: Evolus Q4 Earnings
Evolus (NASDAQ:EOLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus missed... 
Via Benzinga
A Preview Of Evolus's Earnings
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Evolus Reports Second Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus's Earnings: A Preview
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Evolus will report an... 
Via Benzinga
Evolus to Report Second Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
From Evolus
Via Business Wire
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
From Evolus
Via Business Wire
Evolus's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, Evolus's (NASDAQ:EOLS) reported sales totaled $33.91 million. Despite a 3.72% increase in earnings, the company posted a loss of $17.50 million. 
Via Benzinga
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
From Evolus
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Upgrades 
Via Benzinga
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
From Evolus
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
Upgrades 
Via Benzinga
Evolus to Participate in the H.C. Wainwright Global Investment Conference
From Evolus
Via Business Wire
Evolus: Q1 Earnings Insights
Evolus (NASDAQ:EOLS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus beat estimated earnings by 6.06%,... 
Via Benzinga
Evolus Reports First Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus to Report First Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
From Evolus
Via Business Wire
EVOLUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Evolus, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Evolus's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, Evolus (NASDAQ:EOLS) posted sales of $34.66 million. Earnings were up 6.46%, but Evolus still reported an overall loss of $18.18 million... 
Via Benzinga
Evolus Reports Narrower Q4 Loss, CFO Retires, Reaffirms FY22 Outlook
Evolus Inc's (NASDAQ: EOLS) Q4 FY21 sales increased 68% Y/Y to $34.7 million in line with interim results, beating the consensus of $33.99 million, driven... 
Via Benzinga
Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update
From Evolus
Via Business Wire
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®
From Evolus
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.